Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Next Previous
X
Search
Trial Profile

A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belinostat (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BELIEF; Belinostat PTCL
  • Sponsors Spectrum Pharmaceuticals

    • Most Recent Events

    • 06 Nov 2019 Results(N=22), a subset analysis for patients with Angioimmunoblastic T-Cell Lymphoma (AITL) treated with belinostat assessing Overall response rate, released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Jun 2015 According to Onxeo media release, results has been published in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology.
    • 23 Jun 2015 Results published in the Onxeo Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top